2016
DOI: 10.4238/gmr.15026718
|View full text |Cite
|
Sign up to set email alerts
|

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases

Abstract: ABSTRACT. Cardiovascular and cerebrovascular diseases (CCVDs) are common and have high rates of morbidity, mortality, and recurrence. Thrombin-activatable fibrinolysis inhibitor (TAFI) is also known as carboxypeptidase B2 and is encoded by the CPB2 gene; CPB2 polymorphisms have been explored in a variety of studies, but their correlation to the risk of CCVDs remains ambiguous. We examined the hypothesized associations between CPB2 mutations and CCVDs in a general population. We searched, Embase, the Cumulative… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(6 citation statements)
references
References 36 publications
0
6
0
Order By: Relevance
“…TAFI, also named carboxypeptidase B2 or carboxypeptidase U, which is a zymogen synthesized in the liver and present in the plasma of humans, plays an essential role in fibrinolysis by activating plasmin. Moreover, TAFI is incriminated in cardiovascular disorder, such as coronary heart disease, ischemic stroke, angina pectoris, myocardial infarction and venous thrombosis …”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…TAFI, also named carboxypeptidase B2 or carboxypeptidase U, which is a zymogen synthesized in the liver and present in the plasma of humans, plays an essential role in fibrinolysis by activating plasmin. Moreover, TAFI is incriminated in cardiovascular disorder, such as coronary heart disease, ischemic stroke, angina pectoris, myocardial infarction and venous thrombosis …”
Section: Discussionmentioning
confidence: 99%
“…Moreover, TAFI is incriminated in cardiovascular disorder, such as coronary heart disease, ischemic stroke, angina pectoris, myocardial infarction and venous thrombosis. 17 The aim of the current work was to investigate the possible impact of combined genetic variants of VEGF G-1154A gene and two eNOS genes: T-786C promoter region and intron 4 VNTR in addition to TAFI C- 1040 T among Egyptian patients with RSA, which could be a novel highlight on the genetic interaction of the factors affecting angiogenesis, vasoconstrictive and fibrinolytic system, hoping for better understanding of such interactions and to find targeted therapies that can optimize plasma levels of such factors to ameliorate the incidence of RSA. All the studied genetic variants were significantly higher among the RSA patient group than the controls, except for TAFI C-1040Tgenetic variant.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…However, sub-analysis did reveal that TT (Ile/Ile) genotype carriers had a 25% higher risk of coronary heart disease than those with a TC (Thr/Ile) or CC (Thr/Thr) genotype [ 134 ]. In contrast, the results of the meta-analysis of Wang et al supported the independent association of the +1040C/T polymorphism with the extent and severity of cardiovascular and cerebrovascular diseases, especially among Asian populations and more for the development of cardiovascular, than cerebrovascular diseases [ 135 ]. However, it is of note that one of the included studies investigated the association between certain CPB2 SNPs and CVT risk, whereas all other studies focused on arterial thrombosis or coronary artery disease.…”
Section: Plasma Procpu Concentration and Procpu Polymorphisms As Rmentioning
confidence: 99%